The answerable question and a hierarchy of evidence.
Hamilton
John
J
The Permanente Medical Group, Inc., Sacramento, CA, USA. john.hamilton@kp.org
D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D016208:Databases, Factual; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000009:adverse effects / Q000627:therapeutic use*; D010552:Personality Assessment; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use*; D011785:Quality Assurance, Health Care; D016032:Randomized Controlled Trials as Topic; D012984:Software; D016896:Treatment Outcome
D000697:Central Nervous System Stimulants; D011437:Propylamines; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride